Abstract:Anlotinib has been demonstrated to be effective in prolonging progression free survival (PFS; Anlotinib: 5.37 months vs Placebo: 1.40 months) and overall survival (OS; Anlotinib: 9.63 months vs Placebo: 6.30 months) of refractory advanced Non-Small Cell Lung Cancer (NSCLC) patients in clinical trials. Clinical evidences suggested that Anlotinib-induced anti-tumor efficacy could be attributed to anti-angiogenesis. However, the underlying molecular mechanisms and predictive biomarker of Anlotinib are still unclear. 437 patients with advanced NSCLC enrolled in clinical study, and 294 patients received Anlotinib therapy. Retrospectively analysis of the Anlotinib-administrated 294 NSCLC patients was performed to screen out underlying biomarker for Anlotinib-responsive patients. Transcriptome and functional assays were performed to understand the anti-tumor molecular mechanism of Anlotinib in vitro. CCL2 levels and their roles in angiogenesis were evaluated by ELISA detection, RT-qPCR quantification, and immunofluorescence assay, in vivo. Changes in serum CCL2 levels were analyzed to reveal the correlation of Anlotinib response between responders and non-responders. Anlotinib therapy is more beneficial to prolong OS for NSCLC patients harboring positive driver gene mutations, especially for patients harboring EGFRT790M mutation. Moreover, our data indicated that Anlotinib-induced cell viability downregulation, cell apoptosis induction, cell invasion inhibition, cell cycle arrest, and cell migration inhibition are associated with CCL2 levels in vitro. We demonstrated that Anlotinib inhibits angiogenesis of NCI-H1975 derived xenografts model via inhibiting CCL2 in vivo. Lastly, we found that Anlotinib-induced serum CCL2 level decreases are associated with the benefits of PFS and OS, in refractory advanced NSCLC patients (n = 28). Our study reports a novel anti-angiogenesis mechanism of Anlotinib via inhibiting CCL2 in NCI-H1975 derived xenografts model, and suggests the changes in serum CCL2 levels may be used to monitor and predict clinical outcome in Anlotinib-administered refractory advanced NSCLC patients. The biomarker of serum CCL2 alteration may guide precision therapy of Anlotinib for NSCLC patients at third-line or over third-line.

Diethylstilbestrol, a Novel ANO1 Inhibitor, Exerts an Anticancer Effect on Non-Small Cell Lung Cancer via Inhibition of ANO1

Anticancer effect of verteporfin on non-small cell lung cancer via downregulation of ANO1

Inhibition of angiogenesis in cancer by iNOS antisense oligodeoxynucleotide

Downregulation of ANO1 activity in PC‐9 cells modulated by a new novel candidate TMEMinh001

Discovery of a novel natural compound, vitekwangin B, with ANO1 protein reduction properties and anticancer potential

Inhibition of ANO1 by Cis- and Trans-Resveratrol and Their Anticancer Activity in Human Prostate Cancer PC-3 Cells

Cepharanthine, a novel selective ANO1 inhibitor with potential for lung adenocarcinoma therapy

Inhibition of Calcium-Activated Chloride Channel ANO1 Suppresses Proliferation and Induces Apoptosis of Epithelium Originated Cancer Cells

Inhibition of Ca2+-activated Cl− Channel ANO1/TMEM16A Expression Suppresses Tumor Growth and Invasiveness in Human Prostate Carcinoma

ANO1 reprograms cholesterol metabolism and the tumor microenvironment to promote cancer metastasis

Design, Synthesis and Biological Evaluation of Novel Nitric Oxide-Donating Podophyllotoxin Derivatives As Potential Antiproliferative Agents Against Multi-Drug Resistant Leukemia Cells

Design of Anticancer 2,4-Diaminopyrimidines as Novel Anoctamin 1 (ANO1) Ion Channel Blockers

Inhibition of Calcium-Activated Chloride Channel ANO1/TMEM16A Suppresses Tumor Growth and Invasion in Human Lung Cancer

P1.03-16 Anlotinib Inhibits Angiogenesis of Refractory Advanced Non-Small Cell Lung Cancer Via Blocking CCL2 Expression

13-Oxyingenol-dodecanoate inhibits the growth of non-small cell lung cancer cells by targeting ULK1

S-(N,N-diethyldithiocarbamoyl)-N-acetyl-l-cysteine for the treatment of non-small cell lung cancer through regulating NF-κB signalling pathway without neurotoxicity

ANO1 Protein As a Potential Biomarker for Esophageal Cancer Prognosis and Precancerous Lesion Development Prediction.

Novel SERCA2 Inhibitor Diphyllin Displays Anti-Tumor Effect in Non-Small Cell Lung Cancer by Promoting Endoplasmic Reticulum Stress and Mitochondrial Dysfunction

Ornidazole Inhibits the Angiogenesis and Migration Abilities of Non-small Cell Lung

DESC1, a novel tumor suppressor, sensitizes cells to apoptosis by downregulating the EGFR/AKT pathway in esophageal squamous cell carcinoma

Oroxylin A Sensitizes Non-Small Cell Lung Cancer Cells to Anoikis Via Glucose-Deprivation-like Mechanisms: C-Src and Hexokinase II.